Immunometabolic attributes and mitochondria-associated signaling of Tumor-Associated Macrophages in tumor microenvironment modulate cancer progression
Biochemical Pharmacology · 2023-02 · 208 · 115369
DOI: 10.1016/j.bcp.2022.115369 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023-02. Verfasst von Srijan Dubey und 4 weiteren Autor:innen. Beteiligte Einrichtung: Amity Institute of Biotechnology, Amity University, Kolkata, Plot No: 36, 37 & 38, Major Arterial Road, Action Area II, Kadampukur Village, Newtown, …. Hauptthemen laut MEDLINE: Tumor-Associated Macrophages, Neoplasms. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 121 Literaturangaben. Gefördert von: India Ministry of Science & Technology Department of Science and Technology, Science and Engineering Research Board.
Abstract (Originalsprache)
Macrophages are specialized immune cells, which have the capacity to phagocytize and destroy the target cells, including tumor cells. Some macrophages, however on their way to devour the cancer cells undergo a change due to a complex set of signaling pathways. They are induced to change into a polarized state known as M2. The M2 macrophages help in metastasis, tumor suppression, and angiogenesis. The macrophage which gets associated with this TME, are referred to as tumor-associated macrophages (TAMs). TAMS undergo a metabolic reprogramming toward oxidative metabolism for bioenergetic purposes (OXPHOS), fatty acid oxidation (FAO), decreased glycolysis, decreased metabolism via the PPP, and upregulation of arginase 1 (ARG1) which triggers immunosuppressive pro-tumor signaling in the tumor microenvironment (TME) in which mitochondria plays an instrumental role. Reports have suggested that a complex series of interactions and exchange of materials, such as cytokines, metabolic intermediates and sometimes even transfer of mitochondria take place between TAMS and other TME components most importantly cancer cells that reprogram their metabolism to encourage cell growth, division, epithelial to mesenchymal transition, that ultimately play an important role in tumor progression. This review will try to focus on the crosstalk between the TAMs with several other components of TME, what instrumental role mitochondria play in that and also try to explore some of the therapeutic options available in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Amity Institute of Biotechnology, Amity University, Kolkata, Plot No: 36, 37 & 38, Major Arterial Road, Action Area II, Kadampukur Village, Newtown, Kolkata 700135, West Bengal, India.
- Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700032, India.
- Amity Institute of Biotechnology, Amity University, Kolkata, Plot No: 36, 37 & 38, Major Arterial Road, Action Area II, Kadampukur Village, Newtown, Kolkata 700135, West Bengal, India. Electronic address: drudranil@kol.…
Förderung
- India Ministry of Science & Technology Department of Science and Technology
- Science and Engineering Research Board
Zitieren
APA
Dubey, S., Ghosh, S., Goswami, D., Ghatak, D., & De, R. (2023). Immunometabolic attributes and mitochondria-associated signaling of Tumor-Associated Macrophages in tumor microenvironment modulate cancer progression. Biochemical Pharmacology, 208, 115369. https://doi.org/10.1016/j.bcp.2022.115369
Vancouver
Dubey S, Ghosh S, Goswami D, Ghatak D, De R. Immunometabolic attributes and mitochondria-associated signaling of Tumor-Associated Macrophages in tumor microenvironment modulate cancer progression. Biochemical Pharmacology. 2023;208:115369. doi:10.1016/j.bcp.2022.115369
BibTeX
@article{Dubey2023,
author = {Dubey, Srijan and Ghosh, Sayak and Goswami, Debosmita and Ghatak, Debapriya and De, Rudranil},
title = {Immunometabolic attributes and mitochondria-associated signaling of Tumor-Associated Macrophages in tumor microenvironment modulate cancer progression},
journal = {Biochemical Pharmacology},
year = {2023},
volume = {208},
pages = {115369},
doi = {10.1016/j.bcp.2022.115369}
}
EUVIMED